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Introduction. Recent studies have demonstrated the role of the 
interleukin 28B (IL28B) polymorphisms in predicting treatment 
induced and spontaneous clearance from Hepatitis C virus (HCV)
infection, suggesting the possibility of tailored therapy in HCV 
infected patients. Genome-wide association studies have shown 
that single nucleotide polymorphisms (SNPs) near IL 28B gene 
on chromosome 19 are strong predictors of sustained virologic 
response (SVR) to pegylated interferon and ribavirin. This study 
was aimed at analyzing the co-prevalence of two common and 
clinically significant SNPs in a cohort of Ligurian patients.
Methods. Two SNPs (rs12979860, rs8099917) were genotyped 
in the IL28B locus from 175 DNA samples collected from HCV-
infected consecutive patients in a Laboratory of Liguria Region, 
northern Italy. A real-time polymerase chain reaction in a Cor-
bett Research Termocycler (Rotor Gene 3000A) by fluorescent 
probes (Fast Set IL 28B©, Arrow Diagnostics) was used for the 
detection, according to the manufacturer’s instructions.
Results. Carriers of rs12979860CT genotype predominated 
(87/175, 50%), homozygotes for allele C were 68/175 (39%) and 
the remaining were homozygotes for IFN-resistant allele T (11%). 
As for the rs8099917 SNP, genotypes were thus distributed: 96/175 
(55%) carried the rs8099917 TT genotype, whereas 70/175 (40%) 
and 9/175 (5%), were heterozygotes or homozygotes for the G 
allele. The variants rs12979860CC and rs8099917TT were found 
in 39% and 54% of overall patients with HCV genotype 1, respec-
tively. The combined assessment of examined SNPs resulted in 
three most prevalent genotypes (rs12979860CC/rs8099917TT, 
rs12979860CT/rs8099917TG and rs12979860CT/rs8099917TT) 
with a frequency of  35%, 31% and 18%, respectively. 
Discussion. Recent findings demonstrated that in carriers of 
rs12979860CT the determination of additional genotype of 
rs8099917 SNP could significantly improve the prediction of 
SVR. In our study cohort carriers of rs12979860CT represented 
50% of all patients, who could take advantage with respect to 
SVR prediction by further determination of the rs8099917 SNP. 
The simultaneous genotyping of two IL28B SNPs should thus 
be recommended in HCV infected patients prior to treatment 
initiation. 
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Summary
Introduction
Hepatitis C virus (HCV) infection is a global health 
problem with 120–180 million carriers worldwide; 
about 30% of infected individuals develop severe liver 
disease, as it is the leading cause of hepatocellular car-
cinoma, cirrhosis and liver transplants in Europe and the 
USA [1-4]. 
Combination therapy of long-acting pegylated 
interferon-α 2a or 2b (PEG-IFN) and oral treatment 
with ribavirin (RBV) represents the main antiviral tool; 
however, it is unsuccessful in about 50% of cases [5-
8], expensive and associated with significant side ef-
fects, such as hematologic abnormalities, flu-like syn-
drome and adverse neuropsychiatric events, sometimes 
requiring dose reduction or premature termination of 
therapy [9].
In order to reduce several side effects and to avoid the 
heavy medical cost of PEG-IFN/RBV, a clinical tool 
able to predict an individual response before the treat-
ment would be quite useful [10].
Several studies have demonstrated the role of both viral 
factors (such as HCV genotype, baseline viremia) and 
host factors (i.e. age, sex, ethnicity, liver fibrosis, body 
mass index) in predicting the natural course of hepatitis 
C and response to therapy.
A number of genome-wide association studies (GWAS) 
have shown that single nucleotide polymorphisms 
(SNPs) near the interleukin 28B (IL28B) gene on chro-
mosome 19 coding for IFN-3 (rs12979860, rs8099917, 
rs12980275, and rs8103142) [11-16] are strong predic-
tors of sustained virologic response (SVR) to PEG-IFN/
RBV as well as of spontaneous viral clearance in HCV 
infected individuals [17, 18]. Other SNPs of IL28B (rs 
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8105790, rs 11881222, rs 28416813, rs 4803219 and rs 
7248668) have been studied in HCV genotype 1 infected 
patients [17, 19, 20]. 
The SNPs rs12979860 and rs8099917 were found to be 
the most prevalent in different populations and strongly 
associated with treatment outcome. The first one, identi-
fied by Ge et al., has been associated with an approxi-
mately 2-fold difference in SVR rates in type 1-infected 
patients of European, African-American or Hispanic 
ancestry, with its favorable variant rs12979860CC, 
representing the best predictor of SVR in these ethnic 
groups [12, 20, 21-24]. 
The C allele distribution presents a geographical pattern 
with a lower frequency among African individuals than 
European descents [11].
In other studies a non-coding SNP, rs8099917TT, sited 
7.5 kb upstream from the IL28 start codon, has been iden-
tified by Tanaka et al. and Suppiah et al. [14, 15]. These 
GWAS demonstrated that both SNPs (rs12979860, 
rs8099917) are the most critical for therapy outcome, 
in particular the favorable variants, homozygosis for the 
SNPs rs12979860 (CC) and rs8099917 (TT), are signifi-
cantly associated with SVR in HCV-genotype 1–infect-
ed patients treated with Peg-IFN/RBV. 
In the present study we describe genotype and allele 
frequency of IL28B polymorphisms rs12979860 and 
rs8099917 SNPs in 175 DNA samples collected from 
HCV-infected consecutive patients in a Laboratory of 
Liguria Region, northern Italy.
Methods
Genomic DNA was isolated from whole blood samples 
collected from 175 HCV infected patients. In a subset of 
these the following clinical data were available: HCV 
genotype, co-infection with hepatitis B virus (HBV) 
or human immunodeficiency virus (HIV), biochemical 
profile and SVR to antiviral therapy, defined as unde-
tectable HCV RNA levels at least 24 weeks after the end 
of the treatment. 
All the DNA samples were genotyped for two sets of 
IL28B SNPs, rs12979860 and rs8099917, specifying by 
C or T and T or G allele, using a real-time polymerase 
chain reaction (PCR) in a Corbett Research Termocy-
cler (Rotor Gene 3000A) by fluorescent probes (Fast Set 
IL 28B©, Arrow Diagnostics), according to the manu-
facturer’s instructions. The assay discriminated the dif-
ferent genotypes: wild-type homozygote (C/C, T/T), 
heterozygote (C/T, T/G), replaced homozygote (T/T, 
C/C), for rs12979860 and rs8099917, respectively. Flu-
orescence data were measured at the end of every cy-
cle by the following profile: denaturation time of 3 min 
at 95°C, 35 cycle at 95°C for 15 s and 61°C for 45s. 
The results were analyzed using Allelic Discrimination 
Analysis. The samples were tested by duplicate and the 
IL28B genotypes were assigned by analysis of the refer-
ence cycle numbers for each fluorescence curve.
Results
The characteristics of the study cohort are displayed in 
Table I. All patients in the present study were of Cauca-
sian origin. They had a median age of 49 years (range 
22-77 years) and included 121 (69%) men.
HCV genotype 1 was the most frequent (57%), followed 
by genotypes 3 (26%), 4 (12%) and 2 (6%).
Data on HIV and HBV co-infection were known in 
97/104 (93%) and 28/102 (27%) patients, respectively. 
SVR to antiviral therapy was reached by 13/28 (46%) 
patients who received PEG-IFN/RBV.
Carriers of rs12979860CT genotype predominated 
(87/175, 50%), homozygotes for allele C were 68/175 
(39%) and the remaining were homozygotes for IFN-
resistant allele T (11%). As for the rs8099917 SNP, 
genotypes were thus distributed: 96/175 (55%) carried 
the rs8099917 TT genotype, whereas 70/175 (40%) and 
9/175 (5%), were heterozygotes and homozygotes for 
the G allele. 
The frequency of HCV genotypes according to IL 28B 
SNPs (rs1297860 and rs8099917) is depicted in 139 
patients (Fig. 1). The preferred variants rs12979860CC 
and rs8099917TT were found in 39% and 54% of over-
all patients with HCV genotype 1, respectively. Patients 
infected with HCV genotype 2 were the minority in both 
SNPs (6%), whereas those infected with HCV geno-
type 3 were 36% and 20% carriers of rs1297860CC and 
non-CC, 29% and 22% of rs8099917TT and non-TT. 
The frequency of the IFN-resistant allele was 87% for 
rs1297860 and 37% for rs8099917 among all infected 
with HCV genotype 4.
The combined assessment of examined SNPs resulted 
in three most prevalent genotypes (rs12979860CC/
rs8099917TT, rs12979860CT/rs8099917TG and 
Tab. I. Baseline characteristics of study patients.
Variable All patients (n = 175)
Age 49 (22 - 77)
Sex, male (%) 121 (69)
hCv genotype (%) (n=139)
  1
  2
  3
  4
79 (57)
8 (6)
36 (26)
16 (12)
hIv Co-infected (%) (n = 104) 97 (93)
hBv Co-infected (%) (n = 102) 28 (27)
Svr (%) (n = 28) 13 (46)
platelets (n = 58) (x109 L) 167x109 (16x109-406x109)
AST (IU/L) 56.5 (16-376)
ALT (IU/L) 78.5 (14-431)
WBC (/mmc) 5300 (2000-12700)
haemoglobin (g/dl) 14.7 (10.2 - 17.5)
For categorical data, the number of patients is presented, whereas for 
continuous data median and range are shown. AST, alanine aminotrans-
ferase; AST, aspartate aminotransferase; Svr, sustained virological re-
sponse; WBC, white blood cells.
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rs12979860CT/rs8099917TT) with a frequency of 35%, 
31% and 18%, respectively (Fig. 2). The remaining gen-
otypes for the combined two loci were less common and, 
in particular, the variant rs12979860CC/rs8099917GG 
was not observed.
Discussion
In the present study we investigated the prevalence of the 
haplotype and the combined genotyping of rs1297860 
and rs8099917 SNPs in a set of samples of Caucasian 
descendent, by the simultaneous detection of the two 
IL28B loci. The homozygous variants rs1297860CC and 
rs8099917TT, the best predictors of SVR, were found in 
39% and 55% of our cohort.
Several studies have demonstrated the role of IL28B 
polymorphisms in predicting treatment induced and 
spontaneous clearance from HCV infection, suggesting 
the possibility of tailored therapy and its relevant clini-
cal and pharmacoeconomic implications. For example, 
carriers of rs1297860CC infected with HCV genotypes 
1/4 may be haeded towards treatment with PEG-IFN/
RBV, whereas carriers of the IFN-resistant allele T 
with HCV genotype 1 and no advance liver fibrosis 
may defer therapy and wait for new direct-acting an-
tiviral agents  [25]. However, further cost-effective-
ness analyses of response-guided therapy that include 
IL28B genotyping are needed for better understand-
ing how current and future genotyping of other poly-
morphisms may help to evaluate the risk/benefit anti-
viral treatment profile. 
The European Association for the Study of the Liver 
(EASL) Clinical Practice Guidelines for the manage-
ment of HCV infection indicate the determination 
of IL28B variants as an available tool for diagnosis, 
useful to identify patient’s likelihood of response to 
therapy, but with a low predictive value as other ge-
netic variants may show correlation with disease pro-
gression in response to therapy [26]. In the scientific 
literature there is agreement about the need of integra-
tion of IL28B genotyping, which should not be per 
se considered a determining factor in deciding on a 
treatment strategy.
In this matter, a significant issue is which IL28B vari-
ant choose for diagnosis. A recent review by Soriano 
et al. summarized the main findings of GWAS con-
ducted to assess the impact of different IL28B pol-
ymorphisms [25]: the authors underlined that, even 
though multiple SNPs around IL28B gene correlated 
to SVR, such as rs8099917, the current consensus 
considered rs12979860 as the strongest predictor [27]. 
The results of a 2013 meta-analysis confirmed that 
rs12979860CC and rs8099917TT genotypes could be 
used as independent predictors [28]; however, in con-
sideration of the high frequency of rs12979860 in dif-
ferent populations and its relevant effect on treatment 
outcome, the determination of this SNP seemed suf-
ficient for predicting response to therapy [29]. Hal-
fon et al suggested that commercial tests for IL28B 
genotyping should include one simple polymorphism 
to give a simple message to physicians and, because 
of its highest predictive value to SVR, rs12979860 
determination alone should be sufficient to predict 
treatment outcome [30]. In contrast with this opin-
ion, Fisher et al. recently demonstrated that in car-
riers of rs12979860CT the additional genotyping of 
rs8099917 SNP could significantly improve the pre-
diction of SVR [29]. In our study cohort, carriers of 
rs12979860CT represented 50% of all patients, who 
could take advantage with respect to SVR prediction 
by further determination of the rs8099917 SNP. This 
finding is line with the frequency observed by Fisher 
et al.
In conclusion, the simultaneous determination of two 
IL28B SNPs could be useful in some HCV infected pa-
tients to guide therapeutic decisions and improve treat-
ment management and should therefore be included in 
the panel of pre-treatment evaluations.
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Fig. 1. Frequency of hCv genotypes according to IL 28B SNps 
(rs1297860 and rs8099917) in 139 patients.
Fig. 2. distribution (%) of combined genotyping of rs1297860 
and rs8099917 in 175 hCv infected patients.
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